| Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI RA Farrell, D Antony, GR Wall, DA Clark, L Fisniku, J Swanton, Z Khaleeli, ... Neurology 73 (1), 32-38, 2009 | 251 | 2009 |
| Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study J Glasbey, A Ademuyiwa, A Adisa, E AlAmeer, AP Arnaud, F Ayasra, ... The Lancet Oncology 22 (11), 1507-1517, 2021 | 234 | 2021 |
| Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic British Journal of Surgery 108 (1), 88-96, 2021 | 92 | 2021 |
| Patient inclusion in goal setting during early inpatient rehabilitation after acquired brain injury C Dalton, R Farrell, A De Souza, E Wujanto, A McKenna-Slade, ... Clinical Rehabilitation 26 (2), 165-173, 2012 | 66 | 2012 |
| Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNβ in multiple sclerosis patients R Lam, R Farrell, T Aziz, E Gibbs, G Giovannoni, S Grossberg, J Oger Journal of Immunological Methods 336 (2), 113-118, 2008 | 66 | 2008 |
| Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta R Farrell, R Kapoor, S Leary, P Rudge, AJ Thompson, DH Miller, ... Multiple Sclerosis Journal 14 (2), 212-218, 2008 | 66 | 2008 |
| Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis PI Creeke, RA Farrell Therapeutic advances in neurological disorders 6 (1), 3-17, 2013 | 57 | 2013 |
| Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis RA Farrell, G Giovannoni Multiple Sclerosis Journal 13 (5), 567-577, 2007 | 54 | 2007 |
| Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III … J Hobart, T Ziemssen, P Feys, M Linnebank, AD Goodman, R Farrell, ... CNS drugs 33, 61-79, 2019 | 41 | 2019 |
| Disrupted lipid metabolism in multiple sclerosis: a role for liver X receptors? I Pineda-Torra, S Siddique, KE Waddington, R Farrell, EC Jury Frontiers in endocrinology 12, 639757, 2021 | 38 | 2021 |
| Current and future role of interferon beta in the therapy of multiple sclerosis RA Farrell, G Giovannoni Journal of Interferon & Cytokine Research 30 (10), 715-726, 2010 | 34 | 2010 |
| Development of resistance to biologic therapies with reference to IFN-β RA Farrell, M Marta, AJ Gaeguta, V Souslova, G Giovannoni, PI Creeke Rheumatology 51 (4), 590-599, 2012 | 33 | 2012 |
| Intrathecal baclofen for multiple sclerosis related spasticity: a twenty year experience Y Sammaraiee, M Yardley, L Keenan, K Buchanan, V Stevenson, ... Multiple sclerosis and related disorders 27, 95-100, 2019 | 32 | 2019 |
| Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study C Fotopoulou, T Khan, J Bracinik, J Glasbey, N Abu-Rustum, L Chiva, ... American Journal of Obstetrics & Gynecology 227 (5), 735. e1-735. e25, 2022 | 30 | 2022 |
| Using serum metabolomics to predict development of anti-drug antibodies in multiple sclerosis patients treated with IFNβ KE Waddington, A Papadaki, L Coelewij, M Adriani, P Nytrova, ... Frontiers in Immunology 11, 544281, 2020 | 27 | 2020 |
| Emerging therapies in multiple sclerosis R Farrell, D Heaney, G Giovannoni Expert opinion on emerging drugs 10 (4), 797-816, 2005 | 27 | 2005 |
| Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice RA Farrell, M Espasandin, N Lakdawala, PI Creeke, V Worthington, ... Multiple Sclerosis Journal 17 (11), 1333-1340, 2011 | 22 | 2011 |
| Cannabis-based medicinal products: summary of NICE guidance S Chang-Douglass, C Mulvihill, S Pilling Bmj 369, 2020 | 20 | 2020 |
| Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients DK Sato, I Nakashima, T Fukazawa, Y Shimizu, Y Tomizawa, K Yokoyama, ... The Tohoku journal of experimental medicine 228 (2), 85-92, 2012 | 20 | 2012 |
| Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting P Albrecht, IK Bjørnå, D Brassat, R Farrell, P Feys, J Hobart, R Hupperts, ... Therapeutic Advances in Neurological Disorders 11, 1756286418803248, 2018 | 16 | 2018 |
Gavin GiovannoniBarts and The London School of Medicine and DentistryVerified email at giovannoni.net
